Celyad Oncology SA

CYAD

BE0974260896

Biotechnology & Medical Research

Market Closed - Euronext Bruxelles Other stock markets 11:55:00 2026-01-15 am EST			5-day change	1st Jan Change
0.1730 ^EUR	-1.14%		-7.73%	+1.76%

25-09-30	Celyad Oncology to Sell Belgian Research Facility for EUR3 Million	MT
25-09-29	Celyad Oncology announces research facility divestiture	RE

Celyad Oncology to Cancel American Depository Receipt Program in October

Published on 09/26/2023 at 12:38 am EDT - Modified on 09/26/2023 at 12:39 am EDT

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Celyad Oncology SA

25-09-30	Celyad Oncology to Sell Belgian Research Facility for EUR3 Million	MT
25-09-29	Celyad Oncology announces research facility divestiture	RE
25-09-28	An undisclosed buyer agreed to acquire Research facility?s equipment and office furniture in Mont-Saint-Guibert, Belgium of Celyad Oncology SA for ?3 million.	CI
25-09-25	Celyad Oncology SA Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-08-26	Celyad Oncology Announces Discontinuation of R&D Activities and Workforce	CI
25-07-28	Celyad Oncology to Receive EUR1 Million Capital Injection from Shareholder	MT
25-07-27	Celyad Oncology SA announced that it expects to receive ?1 million in funding from CFIP CLYD (UK) Limited	CI
25-06-25	Celyad Oncology Begins Strategic Review Amid Limited Financial Runway	MT
25-06-24	Celyad Oncology Announces Strategic Review	CI
25-04-02	Celyad Oncology SA Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-02-18	Celyad: share price soars on encouraging data
25-02-18	Celyad Oncology Announces the Publication of the Preclinical and Clinical Data of CYAD-211 Providing Proof-Of-Concept of Its miRNA-Based shRNA Platform	CI
24-09-17	Celyad Oncology Names New CEO to Start in October	MT
24-09-16	Celyad Oncology Appoints Matt Kane as Chief Executive Officer, Effective October 1, 2024	CI
24-09-13	Celyad Oncology SA Reports Earnings Results for the Half Year Ended June 30, 2024	CI
24-04-04	Celyad Oncology SA Reports Earnings Results for the Full Year Ended December 31, 2023	CI
24-02-09	Celyad Oncology Seeks Termination of Reporting Obligations to US SEC	MT
23-12-05	Celyad Oncology CEO Resigns	MT
23-12-04	Celyad Oncology CEO Steps Down for Personal Reasons	MT
23-12-04	Celyad Oncology SA Announces Executive Change	CI
23-12-04	Celyad Oncology Sa Announces Executive Change	CI
23-11-13	Celyad Oncology SA announced that it has received ?9.794 million in funding from CFIP CLYD (UK) Limited, Fortress Investment Group LLC, Tolefi S.A.	CI
23-09-26	Celyad Oncology to Cancel American Depository Receipt Program in October	MT
23-09-05	Celyad Oncology SA, H1 2023 Earnings Call, Sep 05, 2023
23-09-04	Celyad Oncology SA Reports Earnings Results for the Half Year Ended June 30, 2023	CI

Celyad Oncology SA is a biotechnology company focused on the discovery and development of innovative technologies chimeric antigen receptor (CAR) T-cell therapies. The company is focusing on opportunities to fully harness the true potential of its proprietary technology platforms and intellectual property and support the development of next-generation CAR T candidates in solid tumors and hematological malignancies.

Employees

Sector

Biotechnology & Medical Research

Calendar

Mar. 18 - Q4 2025 Earnings Release (Projected)

More about the company